Conference Coverage

VIDEO: Researchers closing in on the elusive ‘male pill’


 

REPORTING FROM ENDO 2018

Dimethandrolone, a modified form of testosterone, just might turn out to be the long-sought male contraceptive pill.

It blocks gonadotropin signaling and testosterone production in the testes. When capsules ranging in dose from 100 mg to 400 mg were given once daily to 100 men in a randomized, placebo controlled trial, the drop in testosterone was more than sufficient to block sperm production. Testosterone levels jumped back up to normal after the end of the 28-day trial, all without inducing liver toxicity or other serious problems.

“We are very excited [about] the results. It’s a big step forward in the development of the male pill. Our last great advance in male contraception was over 300 years ago with the development of the condom,” said senior investigator Stephanie Page, MD, PhD, head of the division of metabolism, endocrinology, and nutrition at the University of Washington, Seattle.

Pages

Recommended Reading

ADT not associated with increased risk of dementia in larger study
MDedge Endocrinology
New PAD guidelines expected to boost awareness and treatment
MDedge Endocrinology
Clinicians underusing statins, aspirin in HIV patients
MDedge Endocrinology
Testosterone Trials’ cardiac, cognitive results disappoint
MDedge Endocrinology
Ask patients about sexual function at first visit
MDedge Endocrinology
VIDEO: Low testosterone common after testicular cancer
MDedge Endocrinology
Hypogonadism after testicular cancer treatment can have lifelong impact
MDedge Endocrinology
Meta-analysis shows correlation between diabetes and erectile dysfunction
MDedge Endocrinology
Free testosterone linked to frailty in older men
MDedge Endocrinology
Without reliability, testosterone testing may fall short
MDedge Endocrinology